scholarly journals In SilicoIdentification of Highly Conserved Epitopes of Influenza A H1N1, H2N2, H3N2, and H5N1 with Diagnostic and Vaccination Potential

2015 ◽  
Vol 2015 ◽  
pp. 1-12 ◽  
Author(s):  
José Esteban Muñoz-Medina ◽  
Carlos Javier Sánchez-Vallejo ◽  
Alfonso Méndez-Tenorio ◽  
Irma Eloísa Monroy-Muñoz ◽  
Javier Angeles-Martínez ◽  
...  
Keyword(s):  
Influenza A ◽  
Viral Proteins ◽  
Diagnostic Techniques ◽  
Design Strategies ◽  
Diagnostic Strategies ◽  
Immune Epitope ◽  
Pfam Database ◽  
Influenza A H1n1 ◽  
Primary Problem ◽  
Immune Epitope Database

The unpredictable, evolutionary nature of the influenza A virus (IAV) is the primary problem when generating a vaccine and when designing diagnostic strategies; thus, it is necessary to determine the constant regions in viral proteins. In this study, we completed anin silicoanalysis of the reported epitopes of the 4 IAV proteins that are antigenically most significant (HA, NA, NP, and M2) in the 3 strains with the greatest world circulation in the last century (H1N1, H2N2, and H3N2) and in one of the main aviary subtypes responsible for zoonosis (H5N1). For this purpose, the HMMER program was used to align 3,016 epitopes reported in the Immune Epitope Database and Analysis Resource (IEDB) and distributed in 34,294 stored sequences in the Pfam database. Eighteen epitopes were identified: 8 in HA, 5 in NA, 3 in NP, and 2 in M2. These epitopes have remained constant since they were first identified (~91 years) and are present in strains that have circulated on 5 continents. These sites could be targets for vaccination design strategies based on epitopes and/or as markers in the implementation of diagnostic techniques.

scholarly journals ELISA Method for Detection of Influenza A Infection in Swine

1993 ◽  
Vol 5 (4) ◽  
pp. 510-515 ◽  
Author(s):  
Brian W. Lee ◽  
Russell F. Bey ◽  
Mary J. Baarsch ◽  
Randy R. Simonson
Keyword(s):  
Influenza A ◽  
Swine Influenza ◽  
Diagnostic Techniques ◽  
Distinct Advantage ◽  
Enzyme Linked Immunosorbent Assay ◽  
Virus Shedding ◽  
Elisa System ◽  
Capture Elisa ◽  
Antigen Capture ◽  
Influenza A H1n1

An antigen-capture enzyme-linked immunosorbent assay (ELISA) was developed to monitor virus shedding associated with experimental infection with a field strain of swine influenza in pigs. The assay consisted of a monoclonal anti-nucleoprotein capture antibody and a biotinylated rabbit anti-influenza A (H1N1) sandwich antibody. The antigen-capture system was capable of detecting as little as 1 ng/ml purified virus. The ELISA system surpassed egg cultivation procedures in the detection of low levels of shedding virus. Egg cultivation procedures indicated that most viral shedding had ceased by day 10 postinfection. In contrast, antigen-capture ELISA still showed an ongoing presence of viral antigen. A virus-capture ELISA, using this capture-sandwich antibody system, is equivalent in sensitivity to conventional egg inoculation procedures for the detection of the early phases of virus shedding. The automative potential of an ELISA-based system coupled with a substantially reduced assay time requirement give this virus-capture ELISA a distinct advantage over other cell culture or egg-based diagnostic techniques.

Nachweis bakterieller Superinfektionen bei Patienten mit Influenza A H1N1 mithilfe kultur-unabhängiger molekulargenetischer Typisierung

2010 ◽  
Vol 222 (S 01) ◽  
Author(s):  
M Schiller ◽  
S Eva ◽  
A Halfmann ◽  
HJ Schäfers ◽  
B Gärtner ◽  
...  
Keyword(s):  
Influenza A ◽  
Influenza A H1n1

Narkolepsie nach Impfung gegen die pandemische Influenza A/H1N1/v?

Schlaf ◽  
2013 ◽  
Vol 2 (03) ◽  
pp. 154-160
Author(s):  
Geert Mayer ◽  
Brigitte Keller-Stanislawski ◽  
Doris Oberle
Keyword(s):  
Influenza A ◽  
Influenza A H1n1

Im Herbst/Winter 2009/2010 wurden etwa 30,8 Mio. Menschen in der Europäischen Union mit Pandemrix® gegen die pandemische Influenza A/H1N1/v geimpft. Der von GlaxoSmithKline produzierte Impfstoff war im September 2009 von der Europäischen Kommission als Pandemieimpfstoff zugelassen worden. Im Sommer 2010 wurde erstmals über Fälle einer Narkolepsie bei Kindern und Jugendlichen nach Impfung mit Pandemrix® in Schweden und Finnland berichtet.

Sign in / Sign up

Export Citation Format

Share Document